<DOC>
	<DOCNO>NCT02040623</DOCNO>
	<brief_summary>- To assess efficacy R348 Ophthalmic Solutions administer 12 week subject evaluate objective subjective measure . - To investigate safety tolerability R348 Ophthalmic Solutions administer 12 week subject .</brief_summary>
	<brief_title>Safety Efficacy Study R932348 Ophthalmic Solution Chronic Ocular Graft Versus Host Disease Patients ( DROPS-2 )</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Received Allogeneic hematologic stem cell transplantation least 3 month prior . Subjects post Allogeneic hematologic stem cell transplantation onset worsen dry eye symptom least 1 month prior . Use overthecounter and/or prescription eye drop dry eye symptom within 1 month . Corneal fluorescein stain score ≥ 2 1 region ≥ 1 least 1 region . Total lissamine green conjunctival stain score ( accord modify National Eye Institute grade system ) ≥ 2 . Clinically unstable Graft versus Host Disease ( require change immunosuppressive regimen ) , medical condition , laboratory abnormality Used topical ophthalmic cyclosporine within 45 day . Used topical ophthalmic steroid within 2 week . Used autologous serum eye drop within 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic Graft versus Host Disease</keyword>
	<keyword>Keratoconjunctivitis Sicca</keyword>
</DOC>